Pitts W M, Fann W E, Sajadi C, Snyder S
J Clin Psychiatry. 1983 Jun;44(6):213-5.
Alprazolam, a triazolobenzodiazepine first developed as an anxiolytic, has been shown to be effective in the treatment of depression in several comparison studies with tricyclic antidepressants. This open label study examined the efficacy and safety of alprazolam in patients aged 56-78. Of 18 patients with evaluable data, 12 were responders (improvement greater than or equal to 50% on the Hamilton Depression Rating Scale); 4 patients were partial responders (HAM-D improvement of 25%-49%); and 2 patients were nonresponders. Initial drowsiness was the only side effect observed.
阿普唑仑是一种最初作为抗焦虑药开发的三唑并苯二氮䓬类药物,在与三环类抗抑郁药的多项比较研究中已显示对治疗抑郁症有效。这项开放标签研究考察了阿普唑仑在56至78岁患者中的疗效和安全性。在18例有可评估数据的患者中,12例有反应(汉密尔顿抑郁量表评分改善大于或等于50%);4例为部分反应者(汉密尔顿抑郁量表评分改善25%-49%);2例无反应。观察到的唯一副作用是最初的嗜睡。